The EU Commission accepts a commitment to reduce the price of six cancer medicines by 73% in an excessive pricing case in the pharmaceutical industry (Aspen)

Hall, Samuel

Previous article The EU Commission accepts commitments made by a pharmaceutical company to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns (Aspen) Next article The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen)

10 Feb 2021

The EU Commission accepts a commitment to reduce the price of six cancer medicines by 73% in an excessive pricing case in the pharmaceutical industry (Aspen)

KEYWORDS

Reference

EU Commission, Aspen, Press release, 10 February 2021

On 10 February 2021, the Commission announced that it had accepted a series of pricing and supply commitments from Aspen, thereby bringing an end to its investigation into whether Aspen had infringed Article 102 TFEU by charging excessive prices for six off-patent cancer medicines. Having acquired the cancer medicines from another

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Samuel Hall
Van Bael & Bellis (Brussels)

Belgium 19 contributions 7223 visits

Quotation

Samuel Hall, The EU Commission accepts a commitment to reduce the price of six cancer medicines by 73% in an excessive pricing case in the pharmaceutical industry (Aspen), 10 February 2021, e-Competitions Commitment Decisions, Art. N° 99554

Visites 148